miR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression


MDR1 is highly expressed in MDR A2780DX5 ovarian cancer cells, MDR SGC7901R gastric cancer cells and recurrent tumours. It pumps cytoplasmic agents out of cells, leading to decreased drug accumulation in cells and making cancer cells susceptible to multidrug resistance. Here, we identified that miR-495 was predicted to target ABCB1, which encodes protein MDR1. To reduce the drug efflux and reverse MDR in cancer cells, we overexpressed a miR-495 mimic in SGC7901R and A2780DX cells and in transplanted MDR ovarian tumours in vivo. The results indicated that the expression of MDR1 in the above cells or tumours was suppressed and that subsequently the drug accumulation in the MDR cells was decreased, cell death was increased, and tumour growth was inhibited after treatment with taxol-doxorubicin, demonstrating increased drug sensitivity. This study suggests that pre-treatment with miR-495 before chemotherapy could improve the curative effect on MDR1-based MDR cancer.

DOI: 10.1111/jcmm.13114

6 Figures and Tables

Cite this paper

@inproceedings{Zou2017miR495SM, title={miR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression}, author={Zhenyou Zou and Ruyi Zou and Dan Zong and Yonghong Shi and Jinyao Chen and Jie Huang and Jiahui Zhu and Liguan Chen and Xiaoyan Robert Bao and Yuan Liu and Weihao Liu and Wenhui Huang and Jingsang Hu and Zhi wen Chen and Xiaojie Lao and Chaoqun Chen and Xiaoli Huang and Yao Lu and Xueyin Ni and Daoquan Fang and Dengqiang Wu and Shuangshuang Lu and Mingzhu Jiang and Chenyang Qiu and Yuya Wu and Qisha Qiu and Yanyuan Dong and Yangyang Su and Chenmin Zhao and Zhihe Zhong and Jing Cai and Yong Liang}, booktitle={Journal of cellular and molecular medicine}, year={2017} }